Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway

Since the first clinical report in 2013, inhibitors of the intracellular kinase BTK (BTKi) have profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy with targeted agents in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, C. I. Edvard, Burger, Jan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222783/
https://www.ncbi.nlm.nih.gov/pubmed/34177947
http://dx.doi.org/10.3389/fimmu.2021.689472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222783/
https://www.ncbi.nlm.nih.gov/pubmed/34177947
http://dx.doi.org/10.3389/fimmu.2021.689472

Ejemplares similares